NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced that it has filed an important new patent application in the United States describing the use of its DehydraTECH(TM) technology for the delivery of antiviral drugs. According to the update, the technology would potentially be used to improve treatment options for viral infectious diseases including COVID-19, MERS, SARS, influenza, herpes, hepatitis and AIDS. “Lexaria’s proprietary drug delivery platform has already proven its effectiveness in the oral delivery of other lipophilic drugs such as nicotine, cannabinoids, and more, with multi-fold increases in both the rate and extent of bioabsorption,” Lexaria President John Docherty said in the news release. “We hypothesize that, once detailed testing begins, DehydraTECH will evidence improvements in the quantity and rapidity with which certain antiviral drugs are able to reach the human bloodstream after oral delivery. This has the potential to make a real contribution in the fight against COVID-19.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer